Investing.com - Adaptimmune Therapeutics reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.05 on revenue of $5.54M. Analysts polled by Investing.com anticipated EPS of $-0.29 on revenue of $6.57M.
Adaptimmune Therapeutics shares are down 48.27% from the beginning of the year and are trading at $1.900 , down-from-52-week-high.They are under-performing the Nasdaq which is down 19.03% from the start of the year.
Adaptimmune Therapeutics shares lost 2.06% in pre-market trade the report.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar